ALX Oncology Holdings Inc. (NASDAQ: ALXO) is a Healthcare company (Biotechnology) with a market capitalization of $139M. The Maz Rating grades it against the other companies in its sector.
ALX Oncology Holdings Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.00, ALX Oncology Holdings Inc. trades at 1.1x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -73.4%, return on invested capital of -61.2% and a free cash flow yield of -49.4%. On the balance sheet: a debt-to-equity ratio of 0.08 and a current ratio of 8.04. Over the past 52 weeks the share price ranged from $0.86 to $2.66, with a beta of 0.40.
ALX Oncology Holdings Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 6 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.